QGEN QIAGEN N.V.

QGEN financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 1015820 Exchange: NYSE SIC: 2836 (Biological Products, (No Diagnostic Substances))
Showing 3 of 18 annual and 0 of 0 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Large accelerated filer
Entity Type
Other
Industry (SIC)
2836 Biological Products, (No Diagnostic Substances)
Incorporated
P7
Fiscal Year End
December (1231)
Phone
31-77-35566-00
EIN
000000000
Headquarters
PL VENLO, 5912 PL
Former Names: QIAGEN NV (1998–2020)

▼ Key Metrics (FY 2025)

As of Dec 31, 2025
Financials
Revenue
$2.09B
Net Income
$424.88M
Total Assets
$6.28B
Total Equity
$3.78B
Total Debt
$1.65B
Free Cash Flow
$453.28M
Ratios
Gross Margin
62.2%
Operating Margin
22.3%
Net Margin
20.3%
Return on Equity
11.2%
Return on Assets
6.8%
Current Ratio
3.9x
Debt / Equity
0.44x
FCF / Assets
7.2%
Revenue Growth (YoY)
5.7%
EPS Growth (YoY)
424.3%

▼ FY 2025 Summary Analysis

Annual report ending Dec 31, 2025

Overview and Growth

Fiscal 2025 results for QIAGEN N.V. combined $2.09B of revenue with net income of $424.88M and an operating cash inflow of $654.33M. At $2.09B, the top line establishes the operating scale supporting the company’s profit and cash-flow profile. Revenue was 5.7% above fiscal 2024 revenue of $1.98B, marking a year-over-year increase. Diluted earnings per share were $1.94, translating the period’s attributable earnings into the amount reported for each diluted share. Against diluted EPS of $0.37 in fiscal 2024, the current result was 424.3% higher. Asset turnover was 0.33x, relating the company’s annual revenue directly to the total assets reported at the period end.

Profitability

After reported cost of revenue, the company retained $1.30B as gross profit before recognizing operating expenses and other items. Gross profit represented 62.2% of revenue, showing how much of the top line remained after direct costs. Operations produced $465.85M of income after the reported operating expense base, before the remaining non-operating and tax effects. Operating margin measured 22.3%, showing the portion of revenue preserved after the full set of operating costs. The bottom-line result was net income of $424.88M, after the operating, financing, tax, and other items recognized for the period. The final earnings result represented 20.3% of revenue, connecting the absolute net income figure with the company’s top-line scale. Before income taxes, the company reported $490.26M of earnings, providing a bridge between the operating result and final net income. Measured against revenue, pretax income equaled 23.5%, adding a pre-tax profitability layer between revenue and net income. The company recognized $65.39M of income tax for the period, completing the transition from pretax income to net income. The income-tax provision equaled 13.3% of pretax income, showing the tax burden absorbed by the year’s earnings.

Liquidity and Capital Structure

Total assets were $6.28B, supported by $2.50B of liabilities and $3.78B of shareholder equity. At period end, current assets of $2.00B compared with current liabilities of $512.14M, defining the company’s short-term resource position. The current ratio was 3.9x, with current assets exceeding current liabilities and providing a short-term liquidity cushion. The company held $839.00M in cash and equivalents, a narrower liquidity measure than total current assets. Measured only with cash and equivalents, coverage of current liabilities was 163.8%, excluding receivables and other current assets. Borrowings totaled $1.65B, adding a fixed financing obligation alongside the company’s equity capital. The debt-to-equity relationship was 0.44x, showing how much debt the company carried for each unit of book equity. Debt represented 26.3% of total assets, placing borrowing in the context of the company’s full resource base. Relative to total assets, liabilities measured 39.9%, complementing the separate equity-based view of the company’s capital structure. Cash and equivalents equaled 13.4% of total assets, showing the liquid cash component within the company’s broader resource base.

Cash Flow and Earnings Quality

The company reported $654.33M of operating cash flow, a cash inflow that shows the cash generated by operations. The operating-cash-flow-to-net-income relationship was 1.54x, comparing cash generated by operations with the bottom-line earnings result. Capital expenditures used $201.05M, identifying the reported investment outflow deducted from operating cash flow in the free-cash-flow calculation. Relative to operating cash flow, capital expenditures measured 30.7%, connecting investment intensity with the company’s cash-generation base. The combination of operating cash flow and capital spending produced $453.28M of positive free cash flow for the period. Free cash flow represented 21.7% of revenue, linking post-investment cash generation with the company’s operating scale. Free cash flow equaled 7.2% of total assets, relating post-investment cash generation to the company’s resource base.
Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual (FY)
Quarterly 🔒
Chart 🔒
Annual financial statements for QIAGEN N.V.
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
Revenue $2.09B $1.98B $1.97B
Cost of Revenue $790.50M $1.01B $731.62M
Gross Profit $1.30B $967.35M $1.23B
OPERATING EXPENSES
R&D Expense $187.52M $193.49M $198.51M
SG&A Expense $125.68M $113.43M $119.25M
Other Operating Expenses (derived) $520.45M $562.71M $505.99M
Operating Income $465.85M $97.71M $409.94M
NON-OPERATING INCOME / EXPENSE
Interest Expense - - $53.41M
Interest Income $64.32M $68.02M $78.99M
Other Income/Expense $-6.65M $-739.00K $-5.71M
Pretax Income $490.27M $121.15M $429.81M
Income Tax $65.39M $37.56M $88.51M
Net Income $424.88M $83.59M $341.30M
PER SHARE & SUPPLEMENTAL
Diluted EPS $1.94 $0.37 $1.48
Diluted Shares 218.88M 224.72M 230.62M
EBITDA $659.60M $300.98M $615.27M
Depreciation & Amortization $193.75M $203.27M $205.34M
Balance Sheet
ASSETS
Cash & Equivalents $839.01M $663.56M $668.08M
Short-term Investments $259.91M $489.44M $389.70M
Accounts Receivable $402.61M $349.28M $381.88M
Inventory $301.89M $279.26M $398.39M
Other Current Assets $191.66M $178.33M $309.52M
Current Assets $2.00B $1.96B $2.15B
PP&E (Net) $923.95M $753.61M $765.04M
Goodwill $2.70B $2.43B $2.48B
Intangible Assets $386.43M $303.82M $526.82M
Other Noncurrent Assets $275.12M $246.93M $196.96M
Noncurrent Assets $4.29B $3.73B $3.97B
Total Assets $6.28B $5.69B $6.12B
LIABILITIES
Accounts Payable $72.66M $83.27M $84.16M
Short-term Debt $0 $551.88M $587.97M
Other Current Liabilities $73.37M $82.67M $62.82M
Current Liabilities $512.14M $1.04B $1.08B
Long-term Debt $1.65B $839.67M $921.82M
Other Noncurrent Liabilities $336.51M $240.59M $207.40M
Noncurrent Liabilities $1.99B $1.08B $1.23B
Total Liabilities $2.50B $2.12B $2.31B
EQUITY
Common Stock $2.53M $2.60M $2.70M
Additional Paid-in Capital $1.44B $1.67B $1.92B
Retained Earnings $2.75B $2.45B $2.46B
Accumulated OCI $-377.31M $-474.54M $-433.83M
Total Equity $3.78B $3.57B $3.81B
Total Liabilities & Equity $6.28B $5.69B $6.12B
SUPPLEMENTAL
Total Debt $1.65B $1.39B $1.51B
Shares Outstanding 216.92M 222.29M 228.20M
Check: A − (L + E + NCI) - - -
Cash Flow Statement
Cash from Operations $654.33M $673.55M $459.46M
Capital Expenditures $201.05M $167.17M $149.71M
Cash from Investing $-305.28M $-249.23M $-87.66M
Cash from Financing $-178.98M $-422.90M $-433.83M
Free Cash Flow $453.28M $506.38M $309.75M
Beginning Cash (CFS) $663.56M $668.08M -
Net Change in Cash $170.07M $1.43M -
Effect of FX on Cash $5.38M $-5.96M $-558.00K
Calculated Ending Cash $839.01M $663.56M -
Cash per BS $839.01M $663.56M $668.08M
Cash scope difference (CFS − BS) - - -
Cash per CFS $839.01M $663.56M $668.08M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

What is QIAGEN N.V.'s annual revenue?

QIAGEN N.V. reported $2.09B in revenue for fiscal year 2025 (ending December 2025). Revenue figures are sourced from the company's annual SEC EDGAR filing.

Is QIAGEN N.V. profitable?

Yes. QIAGEN N.V. reported $424.88M in net income for fiscal year 2025. Profitability data is based on the company's most recent annual report filed with the SEC.

What is QIAGEN N.V.'s debt level?

QIAGEN N.V. carries $1.65B in total debt as of fiscal year 2025. Total shareholders' equity stands at $3.78B.

Does QIAGEN N.V. generate free cash flow?

Yes. Free cash flow was $453.28M for fiscal year 2025. Operating cash flow was $654.33M.